Anlon Healthcare Share Price Today

Anlon Healthcare board approves ₹250 crore convertible warrants issue

Anlon Healthcare board approved preferential issue of convertible warrants up to ₹250 crore. Issue targets four investors, including two promoters and two public entities. Warrants have face value of ₹2 each and must be converted within 18 months. 25% consideration payable at allotment, remaining 75% upon share conversion.

Anlon Healthcare shares worth ₹20.54 crore flag large-trade signal

A large-trade signal flagged approximately 6,870,493 Anlon Healthcare shares on NSE. Shares changed hands at ₹29.90 per share, for a combined value of ₹20.54 crore. This is a real-time signal from trade-scanning activity, not a confirmed exchange-reported event. Buyer, seller, and broker identity remain unknown pending any post-market exchange disclosure.

Anlon Healthcare to participate in Arihant Capital conference on Sep 29

Anlon Healthcare Ltd management will join the Arihant Capital 'Bharat Connect Conference' on September 29, 2026. The virtual investor meet is scheduled from 3:00 pm to 4:00 pm IST. The company confirmed no unpublished price sensitive information (UPSI) will be shared during the event. Disclosure made under Regulation 30 of SEBI (LODR) Regulations, 2015.

Anlon Healthcare sets ₹17.85 floor price for share swap acquisitions

Shareholders approved share swap to acquire 44.94% of Apiqo Organics and 47.41% of Bizotic Lifescience. Preferential issue price set at ₹17.85 per share, matching independent valuer's fair value. Floor price derived from 90-day VWAP on NSE, exceeding the 10-day VWAP of ₹14.99. Disclosure lists ultimate beneficial owners for 26 allottees including funds and HUFs.

Anlon Healthcare shareholders approve share capital hike, acquisitions

Shareholders approved a preferential issue of 8,58,83,617 equity shares to acquire Apiqo Organics and Bizotic Lifescience. Authorized share capital was enhanced and the Memorandum of Association altered to support growth initiatives. Punitkumar Rasadia was re-appointed as director; Kishan Vinodkumar Raja appointed as independent director. Audited standalone and consolidated financial statements for FY26 were adopted without qualification.

Anlon Healthcare issues AGM corrigendum for ₹1,533 crore preferential issue

Corrigendum issued to address BSE and NSE queries regarding preferential issue details. Total issue value stands at ₹1,533 crore across AOPL and BLPL components. Shares priced at ₹17.85, aligned with NSE volume-weighted average price of ₹17.78. Promoter stake dilutes from 52.68% to 49.85% post-allotment. Public shareholding increases to 50.15%, meeting regulatory thresholds.